Daiichi Sankyo Company, Limited has launched new generic oxycodone extended release formulations to treat sustained cancer pain: Oxycodone extended release 5 mg, 10 mg, 20 mg and 40 mg "Daiichi Sankyo" (date of approval: August 15, 2016; date of listing in the NHI reimbursement price list in Japan: December 9, 2016).
This oxycodone extended release tablet is an opioid analgesic providing the degree of analgesia prescribed for various cancers with moderate to severe pain, and the first tablet generic for an oxycodone extended release formulation. Our domestic subsidiary, Daiichi Sankyo Propharma Co., Ltd. (manufacturing and marketing) manufactures from drug substance to formulation using our GWATab technology.
Daiichi Sankyo expects this drug to be able to contribute to all patients and medical staff by offering a new therapeutic option.